OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors
J. Weddell
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 12, Iss. 11, pp. 1726-1737
Open Access | Times Cited: 15
J. Weddell
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 12, Iss. 11, pp. 1726-1737
Open Access | Times Cited: 15
Showing 15 citing articles:
Strategies for clinical dose optimization of T cell-engaging therapies in oncology
Kathryn Ball, Simon J. Dovedi, Pavan Vajjah, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 39
Kathryn Ball, Simon J. Dovedi, Pavan Vajjah, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 39
Hyperthermia in Combination with Emerging Targeted and Immunotherapies as a New Approach in Cancer Treatment
Tine Logghe, Eke van Zwol, Benoît Immordino, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 505-505
Open Access | Times Cited: 10
Tine Logghe, Eke van Zwol, Benoît Immordino, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 505-505
Open Access | Times Cited: 10
T-Cell Engagers in Solid Cancers—Current Landscape and Future Directions
Mohamed Shanshal, Paolo F. Caimi, Alex A. Adjei, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2824-2824
Open Access | Times Cited: 20
Mohamed Shanshal, Paolo F. Caimi, Alex A. Adjei, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2824-2824
Open Access | Times Cited: 20
Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology
KyoungSoo Lim, Xu Zhu, Diansong Zhou, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 2, pp. 315-327
Open Access | Times Cited: 8
KyoungSoo Lim, Xu Zhu, Diansong Zhou, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 2, pp. 315-327
Open Access | Times Cited: 8
Development of bispecific T cell engagers: harnessing quantitative systems pharmacology
Timothy Qi, Xiaozhi Liao, Yanguang Cao
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 12, pp. 880-890
Open Access | Times Cited: 14
Timothy Qi, Xiaozhi Liao, Yanguang Cao
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 12, pp. 880-890
Open Access | Times Cited: 14
A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab
Akihiro Yamada, Mary Choules, Frances A. Brightman, et al.
CPT Pharmacometrics & Systems Pharmacology (2025)
Open Access
Akihiro Yamada, Mary Choules, Frances A. Brightman, et al.
CPT Pharmacometrics & Systems Pharmacology (2025)
Open Access
An introduction to quantitative systems pharmacology for chemical engineers
R. Abbiati, César Pichardo‐Almarza
Physical Sciences Reviews (2025)
Closed Access
R. Abbiati, César Pichardo‐Almarza
Physical Sciences Reviews (2025)
Closed Access
Model‐Informed Drug Development Applications and Opportunities in mRNA ‐LNP Therapeutics
Jiawei Zhou, Rohit Rao, Mark Shapiro, et al.
Clinical Pharmacology & Therapeutics (2025)
Open Access
Jiawei Zhou, Rohit Rao, Mark Shapiro, et al.
Clinical Pharmacology & Therapeutics (2025)
Open Access
Dosage Optimization: A Regulatory Perspective for Developing Oncology Drugs
Atiqur Rahman, Mirat Shah, Stacy S. Shord
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 3, pp. 577-591
Open Access | Times Cited: 3
Atiqur Rahman, Mirat Shah, Stacy S. Shord
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 3, pp. 577-591
Open Access | Times Cited: 3
Investigational bispecific antibodies for the treatment of rheumatoid arthritis
Aliki I. Venetsanopoulou, Paraskevi V. Voulgari, Alexandros A. Drosos
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 7, pp. 661-670
Closed Access | Times Cited: 2
Aliki I. Venetsanopoulou, Paraskevi V. Voulgari, Alexandros A. Drosos
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 7, pp. 661-670
Closed Access | Times Cited: 2
Identifying biomarkers for treatment of uveal melanoma by T cell engager using a QSP model
Samira Anbari, Hanwen Wang, Theinmozhi Arulraj, et al.
npj Systems Biology and Applications (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Samira Anbari, Hanwen Wang, Theinmozhi Arulraj, et al.
npj Systems Biology and Applications (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Mechanism-based pharmacokinetic and pharmacodynamic modeling for bispecific antibodies: challenges and opportunities
Jin Niu, Weirong Wang, Danièle Ouellet
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 10, pp. 977-990
Closed Access | Times Cited: 3
Jin Niu, Weirong Wang, Danièle Ouellet
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 10, pp. 977-990
Closed Access | Times Cited: 3
Role of pharmacometrics and systems pharmacology in facilitating efficient dose optimization in oncology
Priya Jayachandran, Rajat Desikan, Sriram Krishnaswami, et al.
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 12, Iss. 11, pp. 1569-1572
Open Access | Times Cited: 1
Priya Jayachandran, Rajat Desikan, Sriram Krishnaswami, et al.
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 12, Iss. 11, pp. 1569-1572
Open Access | Times Cited: 1
Coupling quantitative systems pharmacology modelling to machine learning and artificial intelligence for drug development: its pAIns and gAIns
Núria Folguera-Blasco, Florencia A. T. Boshier, Aydar Uatay, et al.
Frontiers in Systems Biology (2024) Vol. 4
Open Access
Núria Folguera-Blasco, Florencia A. T. Boshier, Aydar Uatay, et al.
Frontiers in Systems Biology (2024) Vol. 4
Open Access
